SoftBank has led the series E round, doubling MIT Media Labs spinout Formlabs’ valuation to $2bn in the process.

SoftBank has led the series E round through its Vision Fund 2, doubling Formlabs’ valuation to $2bn in the process.

Novo Holdings has invested in the immuno-oncology drug developer which already counts 3SBio Group and Eisai as existing backers.

Lilly Asia Ventures has led a $90m series B round for Duality Biologics, which revealed it has now secured $120m altogether from backers also including WuXi Biologics.

Sparx has returned to lead the OUVC-backed cell-based therapeutic technology developer’s series B round, which brought its overall funding to almost $45m.

Checkout.com-backed Thunes has added $60m to its coffers, while Desktop Metal purchased Adaptive3D less than a year after Arkema invested.

Unnamed corporate investors from the healthcare and life science sectors have helped 7wireVentures close its latest healthcare-focused fund.

Nexa3D has confirmed $55m in funding across several rounds, while BukuKas has added $50m to its coffers and both Label Insights and Mya Systems have been acquired.

Novo, SK Group and Amgen have participated in a series C round for the precision therapy developer that has increased its total funding to at least $150m.

Bos, who featured in last year’s GCV Powerlist, has become a general partner at Forbion after spending 12 years at Merck’s corporate venture capital unit.